Amit Tiwari
Concepts (358)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 17 | 2025 | 1222 | 3.710 |
Why?
| | Neoplasms | 18 | 2025 | 1325 | 2.960 |
Why?
| | Apoptosis | 11 | 2024 | 1119 | 2.360 |
Why?
| | Drug Delivery Systems | 12 | 2025 | 154 | 2.170 |
Why?
| | Flavonoids | 5 | 2021 | 54 | 2.170 |
Why?
| | Pinocytosis | 2 | 2025 | 7 | 1.920 |
Why?
| | Skin Absorption | 2 | 2023 | 24 | 1.470 |
Why?
| | Sarcoma, Avian | 3 | 2021 | 10 | 1.410 |
Why?
| | Rous sarcoma virus | 3 | 2021 | 4 | 1.410 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2025 | 326 | 1.350 |
Why?
| | Oxidative Stress | 4 | 2021 | 807 | 1.300 |
Why?
| | Mitosis | 2 | 2021 | 88 | 1.250 |
Why?
| | Cocaine | 2 | 2019 | 177 | 1.120 |
Why?
| | Humans | 70 | 2025 | 52483 | 1.110 |
Why?
| | Cell Proliferation | 6 | 2024 | 1023 | 1.110 |
Why?
| | Animals | 29 | 2025 | 13505 | 0.990 |
Why?
| | Folic Acid | 2 | 2020 | 140 | 0.980 |
Why?
| | Macromolecular Substances | 1 | 2025 | 31 | 0.980 |
Why?
| | Glucosides | 1 | 2025 | 23 | 0.960 |
Why?
| | Endocytosis | 1 | 2025 | 52 | 0.920 |
Why?
| | Benzhydryl Compounds | 1 | 2025 | 68 | 0.910 |
Why?
| | Lysosomes | 2 | 2024 | 76 | 0.910 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2023 | 202 | 0.870 |
Why?
| | Haloperidol | 1 | 2023 | 46 | 0.840 |
Why?
| | Hepatitis B | 1 | 2023 | 16 | 0.840 |
Why?
| | Colonic Neoplasms | 2 | 2023 | 163 | 0.830 |
Why?
| | Toxicity Tests | 2 | 2021 | 57 | 0.820 |
Why?
| | Polyphenols | 3 | 2019 | 38 | 0.810 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2022 | 5 | 0.800 |
Why?
| | Liver Neoplasms | 2 | 2023 | 333 | 0.800 |
Why?
| | Skin | 6 | 2022 | 422 | 0.780 |
Why?
| | Heterocyclic Compounds | 1 | 2022 | 28 | 0.780 |
Why?
| | Hepatitis C | 1 | 2023 | 79 | 0.770 |
Why?
| | Chickens | 3 | 2021 | 107 | 0.760 |
Why?
| | Cell Line, Tumor | 10 | 2025 | 1470 | 0.760 |
Why?
| | Chalcones | 1 | 2021 | 2 | 0.740 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 9 | 0.740 |
Why?
| | Neoplasm Metastasis | 3 | 2021 | 243 | 0.730 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 80 | 0.730 |
Why?
| | Endosomes | 1 | 2021 | 36 | 0.720 |
Why?
| | Nanoparticles | 7 | 2025 | 160 | 0.720 |
Why?
| | Prostatic Neoplasms | 2 | 2024 | 398 | 0.710 |
Why?
| | Chemoprevention | 2 | 2017 | 18 | 0.700 |
Why?
| | Melanoma | 5 | 2022 | 288 | 0.700 |
Why?
| | Allyl Compounds | 1 | 2020 | 11 | 0.690 |
Why?
| | Dietary Supplements | 2 | 2017 | 465 | 0.690 |
Why?
| | Iron | 2 | 2023 | 127 | 0.690 |
Why?
| | Hydrazones | 1 | 2020 | 6 | 0.690 |
Why?
| | Biomedical Research | 1 | 2023 | 256 | 0.670 |
Why?
| | Cosmetics | 1 | 2020 | 4 | 0.670 |
Why?
| | Haptophyta | 1 | 2020 | 5 | 0.660 |
Why?
| | Depression | 1 | 2025 | 600 | 0.660 |
Why?
| | Organic Chemicals | 1 | 2020 | 15 | 0.660 |
Why?
| | Cytokines | 2 | 2024 | 623 | 0.660 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2025 | 403 | 0.660 |
Why?
| | Disease Models, Animal | 2 | 2025 | 1478 | 0.650 |
Why?
| | Healthcare Disparities | 1 | 2023 | 299 | 0.640 |
Why?
| | Nucleus Accumbens | 2 | 2022 | 27 | 0.640 |
Why?
| | Piperazines | 1 | 2020 | 118 | 0.640 |
Why?
| | Iontophoresis | 1 | 2019 | 11 | 0.620 |
Why?
| | Th2 Cells | 1 | 2019 | 23 | 0.620 |
Why?
| | Ultrasonics | 1 | 2019 | 29 | 0.610 |
Why?
| | Th1 Cells | 1 | 2019 | 55 | 0.600 |
Why?
| | Major Histocompatibility Complex | 1 | 2018 | 13 | 0.600 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2018 | 17 | 0.590 |
Why?
| | Alzheimer Disease | 1 | 2022 | 332 | 0.590 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2021 | 299 | 0.590 |
Why?
| | Quinolines | 1 | 2018 | 44 | 0.580 |
Why?
| | Prefrontal Cortex | 1 | 2018 | 85 | 0.570 |
Why?
| | Liposomes | 5 | 2022 | 54 | 0.570 |
Why?
| | Pyrazoles | 1 | 2018 | 114 | 0.540 |
Why?
| | Histone Deacetylase Inhibitors | 4 | 2025 | 58 | 0.540 |
Why?
| | Epigenesis, Genetic | 4 | 2025 | 406 | 0.530 |
Why?
| | Alcohol Drinking | 1 | 2018 | 237 | 0.510 |
Why?
| | Pyrimidines | 1 | 2017 | 199 | 0.500 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 256 | 0.500 |
Why?
| | Ethanol | 1 | 2018 | 342 | 0.490 |
Why?
| | Breast Neoplasms | 4 | 2024 | 1212 | 0.440 |
Why?
| | Antioxidants | 4 | 2022 | 256 | 0.430 |
Why?
| | HCT116 Cells | 2 | 2025 | 30 | 0.430 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 990 | 0.420 |
Why?
| | Eichhornia | 2 | 2022 | 2 | 0.410 |
Why?
| | Drug Discovery | 3 | 2022 | 93 | 0.390 |
Why?
| | Curcumin | 3 | 2021 | 20 | 0.370 |
Why?
| | Iron, Dietary | 1 | 2011 | 7 | 0.360 |
Why?
| | Female | 14 | 2024 | 28171 | 0.360 |
Why?
| | Hematinics | 1 | 2011 | 15 | 0.360 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2011 | 24 | 0.360 |
Why?
| | Excipients | 1 | 2010 | 9 | 0.350 |
Why?
| | Colorectal Neoplasms | 2 | 2025 | 294 | 0.340 |
Why?
| | Peptides | 1 | 2010 | 223 | 0.320 |
Why?
| | HEK293 Cells | 2 | 2021 | 229 | 0.310 |
Why?
| | Drug Carriers | 3 | 2021 | 73 | 0.300 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 460 | 0.290 |
Why?
| | Structure-Activity Relationship | 5 | 2023 | 404 | 0.290 |
Why?
| | Proteins | 1 | 2010 | 348 | 0.280 |
Why?
| | Nanotubes, Carbon | 2 | 2022 | 69 | 0.270 |
Why?
| | Administration, Oral | 3 | 2021 | 451 | 0.270 |
Why?
| | Biological Availability | 5 | 2024 | 108 | 0.260 |
Why?
| | RNA, Messenger | 2 | 2020 | 1132 | 0.260 |
Why?
| | Doxorubicin | 3 | 2024 | 241 | 0.250 |
Why?
| | Biomass | 5 | 2022 | 21 | 0.240 |
Why?
| | Swine | 2 | 2024 | 428 | 0.240 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2025 | 28 | 0.240 |
Why?
| | Male | 8 | 2025 | 26761 | 0.240 |
Why?
| | Paclitaxel | 1 | 2025 | 89 | 0.240 |
Why?
| | Skin Neoplasms | 2 | 2021 | 505 | 0.230 |
Why?
| | Lipids | 3 | 2021 | 155 | 0.230 |
Why?
| | Limonins | 1 | 2024 | 1 | 0.230 |
Why?
| | Polyurethanes | 1 | 2024 | 10 | 0.220 |
Why?
| | Brain Neoplasms | 2 | 2025 | 291 | 0.220 |
Why?
| | Movement Disorders | 1 | 2024 | 16 | 0.220 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2021 | 178 | 0.220 |
Why?
| | Acute Pain | 1 | 2024 | 11 | 0.220 |
Why?
| | Hydrops Fetalis | 1 | 2023 | 2 | 0.220 |
Why?
| | Behavior, Animal | 1 | 2025 | 185 | 0.220 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2024 | 80 | 0.220 |
Why?
| | Eye | 1 | 2024 | 25 | 0.220 |
Why?
| | Petroleum Pollution | 1 | 2024 | 26 | 0.220 |
Why?
| | Capsaicin | 1 | 2023 | 14 | 0.220 |
Why?
| | Lorazepam | 1 | 2023 | 12 | 0.220 |
Why?
| | Kinetics | 5 | 2022 | 626 | 0.210 |
Why?
| | Diphenhydramine | 1 | 2023 | 18 | 0.210 |
Why?
| | Trypanosomiasis | 1 | 2023 | 1 | 0.210 |
Why?
| | Trypanosoma | 1 | 2023 | 2 | 0.210 |
Why?
| | Cyclosporine | 1 | 2024 | 67 | 0.210 |
Why?
| | Molecular Targeted Therapy | 2 | 2022 | 133 | 0.210 |
Why?
| | Toll-Like Receptor 5 | 1 | 2023 | 5 | 0.210 |
Why?
| | Cell Survival | 2 | 2024 | 612 | 0.210 |
Why?
| | Mice | 5 | 2025 | 5949 | 0.210 |
Why?
| | Retinal Diseases | 1 | 2024 | 56 | 0.210 |
Why?
| | Cholestasis | 1 | 2023 | 40 | 0.200 |
Why?
| | Stress, Psychological | 1 | 2025 | 273 | 0.200 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 8 | 0.200 |
Why?
| | Cyclodextrins | 1 | 2022 | 18 | 0.200 |
Why?
| | Colitis | 1 | 2023 | 51 | 0.200 |
Why?
| | Silicon Dioxide | 1 | 2022 | 15 | 0.200 |
Why?
| | Administration, Cutaneous | 2 | 2022 | 55 | 0.200 |
Why?
| | Analgesics | 1 | 2024 | 107 | 0.200 |
Why?
| | Fetus | 1 | 2023 | 194 | 0.200 |
Why?
| | Glioblastoma | 1 | 2024 | 97 | 0.200 |
Why?
| | Climate Change | 1 | 2023 | 53 | 0.200 |
Why?
| | Signal Transduction | 4 | 2024 | 1671 | 0.200 |
Why?
| | Biofuels | 1 | 2022 | 6 | 0.200 |
Why?
| | Treatment Outcome | 2 | 2023 | 5422 | 0.200 |
Why?
| | Holography | 1 | 2022 | 1 | 0.190 |
Why?
| | Nitrogen | 1 | 2022 | 70 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 182 | 0.190 |
Why?
| | Aegle | 1 | 2021 | 1 | 0.190 |
Why?
| | Patents as Topic | 1 | 2022 | 10 | 0.190 |
Why?
| | Eye Infections | 1 | 2021 | 4 | 0.190 |
Why?
| | Oncolytic Viruses | 1 | 2022 | 13 | 0.190 |
Why?
| | Oncolytic Virotherapy | 1 | 2022 | 21 | 0.190 |
Why?
| | Keratitis | 1 | 2021 | 12 | 0.190 |
Why?
| | Delayed-Action Preparations | 3 | 2024 | 55 | 0.190 |
Why?
| | HT29 Cells | 1 | 2021 | 14 | 0.190 |
Why?
| | Patient Care | 1 | 2022 | 57 | 0.190 |
Why?
| | Medical Oncology | 1 | 2022 | 104 | 0.180 |
Why?
| | Cathepsins | 1 | 2021 | 6 | 0.180 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2021 | 39 | 0.180 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2021 | 7 | 0.180 |
Why?
| | Phosphatidylcholines | 1 | 2021 | 27 | 0.180 |
Why?
| | Environmental Pollutants | 1 | 2022 | 106 | 0.180 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 20 | 0.180 |
Why?
| | Cricetulus | 1 | 2021 | 104 | 0.180 |
Why?
| | CHO Cells | 1 | 2021 | 125 | 0.180 |
Why?
| | Water Purification | 1 | 2021 | 10 | 0.180 |
Why?
| | Biological Transport | 1 | 2021 | 160 | 0.180 |
Why?
| | Catechols | 1 | 2020 | 8 | 0.180 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 88 | 0.180 |
Why?
| | Drug Stability | 3 | 2021 | 38 | 0.170 |
Why?
| | HeLa Cells | 1 | 2021 | 265 | 0.170 |
Why?
| | Zebrafish | 1 | 2021 | 59 | 0.170 |
Why?
| | Water Pollutants, Chemical | 1 | 2021 | 54 | 0.170 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2018 | 136 | 0.170 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2020 | 12 | 0.170 |
Why?
| | Lead | 1 | 2020 | 33 | 0.170 |
Why?
| | Drug Resistance | 1 | 2020 | 65 | 0.170 |
Why?
| | Amides | 1 | 2020 | 37 | 0.170 |
Why?
| | Prospective Studies | 2 | 2020 | 2481 | 0.170 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 194 | 0.170 |
Why?
| | Water Loss, Insensible | 1 | 2020 | 1 | 0.170 |
Why?
| | Acyclovir | 1 | 2020 | 8 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2022 | 115 | 0.170 |
Why?
| | Anemia | 1 | 2020 | 74 | 0.170 |
Why?
| | Prevalence | 1 | 2023 | 1006 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 125 | 0.160 |
Why?
| | Drug Design | 1 | 2020 | 120 | 0.160 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 1884 | 0.160 |
Why?
| | Chemokines | 1 | 2019 | 79 | 0.160 |
Why?
| | Lidocaine | 1 | 2020 | 46 | 0.160 |
Why?
| | Autophagy | 1 | 2021 | 193 | 0.160 |
Why?
| | Ceramides | 1 | 2019 | 34 | 0.160 |
Why?
| | Protein Binding | 1 | 2021 | 667 | 0.160 |
Why?
| | Cell Cycle | 1 | 2020 | 230 | 0.160 |
Why?
| | Cell Movement | 1 | 2020 | 268 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 227 | 0.160 |
Why?
| | Pandemics | 2 | 2022 | 585 | 0.160 |
Why?
| | Drug Resistance, Multiple | 1 | 2019 | 24 | 0.150 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2019 | 34 | 0.150 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 153 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1031 | 0.150 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2020 | 339 | 0.150 |
Why?
| | Dipeptides | 1 | 2018 | 21 | 0.150 |
Why?
| | Cell Line | 1 | 2021 | 1030 | 0.150 |
Why?
| | Thermogravimetry | 3 | 2022 | 7 | 0.150 |
Why?
| | Inflammation Mediators | 1 | 2019 | 115 | 0.150 |
Why?
| | Haplotypes | 1 | 2018 | 92 | 0.140 |
Why?
| | Lignans | 1 | 2017 | 7 | 0.140 |
Why?
| | Hydroxybenzoates | 1 | 2017 | 24 | 0.140 |
Why?
| | Cell Nucleus | 1 | 2018 | 187 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 144 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 178 | 0.140 |
Why?
| | Stilbenes | 1 | 2017 | 58 | 0.130 |
Why?
| | Up-Regulation | 1 | 2019 | 454 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 57 | 0.130 |
Why?
| | Pregnancy | 2 | 2023 | 2680 | 0.130 |
Why?
| | Substance-Related Disorders | 1 | 2022 | 609 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
| | Young Adult | 2 | 2020 | 4329 | 0.130 |
Why?
| | Molecular Structure | 1 | 2017 | 314 | 0.130 |
Why?
| | Gene Expression | 1 | 2019 | 618 | 0.130 |
Why?
| | Particle Size | 3 | 2021 | 82 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 1 | 2020 | 1563 | 0.130 |
Why?
| | Solubility | 3 | 2021 | 79 | 0.120 |
Why?
| | Obesity | 1 | 2023 | 1162 | 0.120 |
Why?
| | Adult | 4 | 2023 | 14161 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1378 | 0.110 |
Why?
| | Pharmaceutical Preparations | 2 | 2024 | 77 | 0.100 |
Why?
| | Rats | 1 | 2018 | 3220 | 0.100 |
Why?
| | Lipid Bilayers | 2 | 2022 | 12 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1323 | 0.090 |
Why?
| | Polymers | 2 | 2023 | 49 | 0.090 |
Why?
| | Polyethylene Glycols | 2 | 2022 | 90 | 0.090 |
Why?
| | Drug Compounding | 2 | 2021 | 28 | 0.090 |
Why?
| | Drug Storage | 1 | 2010 | 2 | 0.090 |
Why?
| | Dendrimers | 1 | 2010 | 2 | 0.090 |
Why?
| | Microspheres | 1 | 2010 | 21 | 0.090 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2010 | 35 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2011 | 119 | 0.090 |
Why?
| | Immunotherapy | 2 | 2023 | 244 | 0.080 |
Why?
| | DNA Methylation | 2 | 2025 | 592 | 0.080 |
Why?
| | Glutathione | 1 | 2011 | 305 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2011 | 554 | 0.080 |
Why?
| | Inflammation | 2 | 2024 | 641 | 0.080 |
Why?
| | Prognosis | 2 | 2024 | 2099 | 0.070 |
Why?
| | Multiple Myeloma | 1 | 2021 | 3049 | 0.060 |
Why?
| | Platinum Compounds | 1 | 2025 | 11 | 0.060 |
Why?
| | Drug Synergism | 1 | 2025 | 150 | 0.060 |
Why?
| | Administration, Ophthalmic | 1 | 2024 | 2 | 0.060 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 20 | 0.060 |
Why?
| | Dopaminergic Neurons | 1 | 2024 | 19 | 0.060 |
Why?
| | Methyltransferases | 1 | 2024 | 29 | 0.060 |
Why?
| | Emulsions | 1 | 2024 | 25 | 0.050 |
Why?
| | Nanotechnology | 1 | 2024 | 41 | 0.050 |
Why?
| | Anthracyclines | 1 | 2024 | 32 | 0.050 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 78 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 81 | 0.050 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2024 | 54 | 0.050 |
Why?
| | Homozygote | 1 | 2023 | 59 | 0.050 |
Why?
| | Droughts | 1 | 2023 | 12 | 0.050 |
Why?
| | Succinic Acid | 1 | 2023 | 3 | 0.050 |
Why?
| | Dextran Sulfate | 1 | 2023 | 8 | 0.050 |
Why?
| | Zinc | 1 | 2024 | 56 | 0.050 |
Why?
| | India | 1 | 2023 | 68 | 0.050 |
Why?
| | Inulin | 1 | 2023 | 10 | 0.050 |
Why?
| | Agriculture | 1 | 2023 | 18 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 71 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2024 | 171 | 0.050 |
Why?
| | Antigens, Protozoan | 1 | 2023 | 12 | 0.050 |
Why?
| | Horses | 1 | 2023 | 49 | 0.050 |
Why?
| | Patient Selection | 1 | 2025 | 259 | 0.050 |
Why?
| | Computational Biology | 1 | 2025 | 212 | 0.050 |
Why?
| | Dogs | 1 | 2023 | 180 | 0.050 |
Why?
| | Deuterium | 1 | 2023 | 46 | 0.050 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2022 | 2 | 0.050 |
Why?
| | Glutamates | 1 | 2022 | 21 | 0.050 |
Why?
| | beta-Lactams | 1 | 2022 | 31 | 0.050 |
Why?
| | Cardiolipins | 1 | 2022 | 2 | 0.050 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 24 | 0.050 |
Why?
| | Porosity | 1 | 2022 | 31 | 0.050 |
Why?
| | Daunorubicin | 1 | 2022 | 13 | 0.050 |
Why?
| | Bile Acids and Salts | 1 | 2023 | 80 | 0.050 |
Why?
| | Phosphorylcholine | 1 | 2022 | 20 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2022 | 64 | 0.050 |
Why?
| | Anaerobiosis | 1 | 2022 | 20 | 0.050 |
Why?
| | Phylogeny | 1 | 2023 | 231 | 0.050 |
Why?
| | Methane | 1 | 2022 | 11 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2023 | 184 | 0.050 |
Why?
| | Silver | 1 | 2022 | 52 | 0.050 |
Why?
| | Digestion | 1 | 2022 | 29 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 206 | 0.050 |
Why?
| | Lecithins | 1 | 2022 | 1 | 0.050 |
Why?
| | Phenylethyl Alcohol | 1 | 2022 | 5 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2022 | 97 | 0.050 |
Why?
| | Chemokine CCL5 | 1 | 2021 | 9 | 0.050 |
Why?
| | Genetic Variation | 1 | 2023 | 230 | 0.050 |
Why?
| | Surface-Active Agents | 1 | 2022 | 10 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2022 | 104 | 0.050 |
Why?
| | Solid Waste | 1 | 2021 | 2 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 243 | 0.050 |
Why?
| | RNA, Viral | 1 | 2022 | 127 | 0.050 |
Why?
| | Cholesterol | 1 | 2022 | 153 | 0.050 |
Why?
| | Mammals | 1 | 2022 | 61 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 63 | 0.050 |
Why?
| | Microscopy | 1 | 2022 | 60 | 0.050 |
Why?
| | Cadaver | 1 | 2022 | 96 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 639 | 0.050 |
Why?
| | RNA | 1 | 2022 | 168 | 0.050 |
Why?
| | Adenosine | 1 | 2022 | 71 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2021 | 51 | 0.050 |
Why?
| | Snakes | 1 | 2021 | 1 | 0.050 |
Why?
| | Histones | 1 | 2023 | 314 | 0.050 |
Why?
| | Necrosis | 1 | 2022 | 176 | 0.050 |
Why?
| | Gallbladder Neoplasms | 1 | 2021 | 7 | 0.050 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 6 | 0.050 |
Why?
| | Cholecystitis | 1 | 2021 | 10 | 0.050 |
Why?
| | Transcription Factor RelA | 1 | 2021 | 32 | 0.050 |
Why?
| | Adsorption | 1 | 2021 | 19 | 0.050 |
Why?
| | Permeability | 1 | 2021 | 66 | 0.050 |
Why?
| | Amino Acids | 1 | 2023 | 377 | 0.050 |
Why?
| | Cell Death | 1 | 2022 | 177 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2022 | 179 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 610 | 0.040 |
Why?
| | Half-Life | 1 | 2021 | 88 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 95 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 132 | 0.040 |
Why?
| | Click Chemistry | 1 | 2020 | 3 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2021 | 117 | 0.040 |
Why?
| | Fruit | 1 | 2021 | 128 | 0.040 |
Why?
| | Phenotype | 1 | 2023 | 789 | 0.040 |
Why?
| | Carbamates | 1 | 2020 | 16 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 220 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2023 | 879 | 0.040 |
Why?
| | Urea | 1 | 2020 | 82 | 0.040 |
Why?
| | Limit of Detection | 1 | 2020 | 21 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 221 | 0.040 |
Why?
| | Triazoles | 1 | 2020 | 115 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 188 | 0.040 |
Why?
| | Quercetin | 1 | 2019 | 18 | 0.040 |
Why?
| | Catechin | 1 | 2019 | 16 | 0.040 |
Why?
| | NF-kappa B | 1 | 2021 | 322 | 0.040 |
Why?
| | Epidermis | 1 | 2019 | 32 | 0.040 |
Why?
| | Calorimetry, Differential Scanning | 1 | 2019 | 8 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 364 | 0.040 |
Why?
| | Pyridines | 1 | 2020 | 132 | 0.040 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2019 | 45 | 0.040 |
Why?
| | Linear Models | 1 | 2020 | 287 | 0.040 |
Why?
| | Xenorhabdus | 1 | 2018 | 1 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2018 | 25 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 171 | 0.040 |
Why?
| | Mutation | 1 | 2024 | 1347 | 0.040 |
Why?
| | Cell Membrane | 1 | 2019 | 245 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2018 | 101 | 0.040 |
Why?
| | Middle Aged | 2 | 2023 | 13028 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 807 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 1229 | 0.030 |
Why?
| | Aged | 1 | 2021 | 10121 | 0.020 |
Why?
|
|
Tiwari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|